BMS-986020 sodium

• CAT Number: I018303
• CAS Number: 1380650-53-2
• Molecular Formula: C29H25N2NaO5
• Molecular Weight: 504.51
• Purity: ≥95%
• Synonyms: sodium;1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylate
• IUPAC Name: sodium 1-[4-[4-[3-methyl-4-[[(1R)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]cyclopropane-1-carboxylate
• InChI: InChI=1S/C29H26N2O5.Na/c1-18-25(30-28(34)35-19(2)20-6-4-3-5-7-20)26(36-31-18)23-10-8-21(9-11-23)22-12-14-24(15-13-22)29(16-17-29)27(32)33;/h3-15,19H,16-17H2,1-2H3,(H,30,34)(H,32,33);/q;+1/p-1/t19-;/m1./s1
• InChIKey: QDCOVTLBRMPIMY-FSRHSHDFSA-M
• SMILES: CC1=NOC(=C1NC(=O)O[C@H](C)C2=CC=CC=C2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5(CC5)C(=O)[O-].[Na+]

BMS-986020 sodium（Cat No.:I018303）is a selective antagonist of lysophosphatidic acid receptor 1 (LPA₁), a G protein–coupled receptor implicated in fibrosis, inflammation, and cancer progression. By blocking LPA₁ signaling, BMS-986020 reduces fibroblast activation, collagen deposition, and tissue remodeling. It has been investigated in clinical trials for idiopathic pulmonary fibrosis (IPF), showing antifibrotic activity, though development was limited by liver-related adverse effects. In research, BMS-986020 sodium is used to probe LPA signaling pathways, offering valuable insights into fibrotic disease mechanisms and therapeutic strategies targeting LPA-mediated pathophysiology.